About Kylin Therapeutics
Kylin Therapeutics, a biotechnology company, employs a RNA nanoparticle technology platform called"pRNA" to exploit the potential of RNA interference (RNAi) for treatment of many common diseases including cancer.
Missing: Kylin Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Kylin Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Kylin Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Kylin Therapeutics is included in 3 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Kylin Therapeutics Frequently Asked Questions (FAQ)
Where is Kylin Therapeutics's headquarters?
Kylin Therapeutics's headquarters is located at 3000 Kent Avenue, West Lafayette.
What is Kylin Therapeutics's latest funding round?
Kylin Therapeutics's latest funding round is Unattributed.
How much did Kylin Therapeutics raise?
Kylin Therapeutics raised a total of $4.4M.
Who are the investors of Kylin Therapeutics?
Investors of Kylin Therapeutics include Golden Pine Ventures, In-vivo Ventures, Elevate Ventures and Heartland Angels.
Who are Kylin Therapeutics's competitors?
Competitors of Kylin Therapeutics include Larimar Therapeutics, Seattle Genetics, PDS Biotechnology, Endocyte, Celtaxsys and 12 more.
Compare Kylin Therapeutics to Competitors
Algae Biosciences Corporation ("AlgaeBio") is a biotechnology company that aims to produce ultra-pure products from microalgae and macroalgae in a facility located near Holbrook, Arizona. The company has been producing microalgae on a small scale since October 2006. It aims to offer, per the company, the tools for harnessing the potential of the most prolific, abundant resource on the company's planet: the 200,000-plus known species of algae. Each species aims to offer downstream product potentials.
Innodia Inc is a biotechnology company engaged in taking to the market drugs for the treatment of type 2 diabetes and related diseases and in generating value for its shareholders
Halsa Pharmaceuticals is a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases.
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.